Global Antimicrobial Resistance Surveillance Market Size, Share & Trends Analysis Report By End-user, By Region, and Segment Forecasts, 2023 - 2030

Global Antimicrobial Resistance Surveillance Market Size, Share & Trends Analysis Report By End-user, By Region, and Segment Forecasts, 2023 - 2030

Global Antimicrobial Resistance Surveillance Market Size, Share & Trends Analysis Report By End-user, By Region, and Segment Forecasts, 2023 – 2030

Global Antimicrobial Resistance Surveillance market was valued US$ 5.6 Billion in 2022 and is expected to reach ~US$ 9.9 Billion by 2032, growing at a CAGR of 5.8% during the forecast period 2023-2032.

AMR, or antimicrobial resistance, is one of the current most pressing issues in public health. In order to solve this challenge, the global market for antimicrobial resistance surveillance is essential. treatments designed to combat microorganisms, such as viruses and bacteria, lose some of their effectiveness or stop working completely when these microbes acquire resistance to the treatments. This market has grown as a result of the urgent demand for reliable monitoring systems, which enable medical practitioners to make well-informed judgements about the prescription of antibiotics and treatment plans.

The use of data analytics, information sharing platforms, and sophisticated laboratory procedures are key components of the worldwide antimicrobial resistance surveillance industry. These tools make it easier to gather and analyse data from clinics, labs, and healthcare facilities all over the world. Healthcare stakeholders can now recognise growing patterns of resistance, design focused interventions, and produce innovative antimicrobial medications thanks to this data-driven approach. The significant disease burden brought on by pathogens such as Streptococcus pneumonia, MRSA, C. difficile infections, and others, as well as a discernible rise in the incidence of AMR infections, are the main factors propelling the market's expansion. In order to effectively combat AMR, there is also a growing need for sophisticated diagnostic solutions, and the growing number of regulatory approvals for diagnostic goods is anticipated to support market expansion even more.

Nonetheless, the lack of uniform protocols and standards for AMR surveillance may impede the comparability and interoperability of data across various nations and regions. One of the challenges in creating a coherent global surveillance network is this lack of standardisation. The growing prevalence of infections brought on by drug-resistant pathogens, improvements in diagnostic technologies, growing concern over antimicrobial resistance, government initiatives to combat antimicrobial-resistant species, and the emergence of multi-drug resistance as a result of substance abuse are all contributing factors to the growth of the antimicrobial resistance surveillance market. On the other hand, the market's expansion is being limited by the high costs of antimicrobial resistance diagnostic kits and systems.

“Kits segment, by type, to be dominating market from 2023 to 2030.”

The worldwide antimicrobial resistance surveillance market comprises four main segments: kits, systems, surveillance software, and services. The kits market contributed significantly to the worldwide antimicrobial resistance surveillance market in 2022. These kits include consumables and diagnostic reagents that are used in labs to identify and find microorganisms that are resistant to antibiotics. They are necessary for carrying out microbiological analyses intended to identify the traits of infectious agent resistance. Culture media, molecular testing reagents, and antibiotic susceptibility testing (AST) panels are a few examples of such kits.

“Public health surveillance segment, by application, to be largest market from 2023 to 2030.”

The application segment of the antimicrobial resistance surveillance market is sub-segmented into clinical diagnostics, public health surveillance and other applications. Surveillance methods are employed in clinical diagnostics to track the patterns of infectious agent resistance inside healthcare institutions. This includes medical facilities such as clinics, hospitals, and labs where prompt detection of drug-resistant microorganisms is essential for patient care. The market study in public health surveillance concentrates on information that is utilised to create regulations, policies, and public health plans to stop and control the spread of resistant microorganisms.

“Hospital segment, by end user, to be largest market from 2023 to 2030.”

Regarding the end-user breakdown, the Antimicrobial Resistance Surveillance market is categorized into hospitals & clinics, research & academic institutions and others. In 2022, the hospital segment commanded a dominant share of 45% in sales due to its strong market position. The rising rate of hospital-acquired infections, an increase in hospital admissions as a result of AMR infections, extended hospital stays, easier access to cutting-edge diagnostic tools, affordability, and better healthcare coverage are some of the reasons for this dominance. Furthermore, dangerous infections including bloodstream infections, sepsis, pneumonia, and surgical site infections can be brought on by pathogenic infections like MRSA, CDI, and DRSP. Consequently, the increased prevalence of pathogen-related illnesses in hospital environments supports this market's expansion even more. In addition, a research carried out in April 2022 by BD, Pfizer, and Merck found that during the COVID-19 pandemic, more than 270 US hospitals observed a rise in antibiotic resistance.

On the other hand, the market for diagnostic laboratories is anticipated to grow at the fastest rate in the approaching years. The rising prevalence of infectious diseases and improvements in laboratory technologies support this trajectory. Furthermore, the rise of the market is expected to be driven by the accessibility of reasonably priced services and the prevalence of laboratories performing a wide range of diagnostic procedures. Laboratory testing is essential to patient care because it can identify new risks, track them down, and offer accurate data that can be used to guide treatment choices. In order to facilitate quick resistance identification and alert local authorities for coordinated actions to stop its spread, the CDC launched the AR laboratory network.

“North America to be largest region in Antimicrobial Resistance Surveillance Market.”

North America, which includes nations like the United States and Canada, is home to developed healthcare systems and cutting-edge laboratory facilities. These countries devote significant resources to the surveillance of antimicrobial resistance (AMR), emphasising clinical diagnosis and rigorous data collection. Because of the region's strong healthcare system and high patient care standards, clinical diagnostics have gained a substantial market share in North America. The Centres for Disease Control and Prevention (CDC) are in charge of AMR surveillance activities in the US. In the meanwhile, the Asia Pacific area is anticipated to have the fastest growth rate in the worldwide antimicrobial resistance surveillance market over the forecast period. Particularly China has established a nationwide data collection network and made significant investments in AMR surveillance. Additionally, the Asia-Pacific region works with global institutions such as the World Health Organisation (WHO). The Asia-Pacific region, which includes nations like China and India, has unique issues because of its heterogeneous healthcare systems and varied population proportions. The public health surveillance landscape in this region is expanding due to the efforts and organisations working in the fields of global and regional health.

Antimicrobial Resistance Surveillance Competitive Landscape

The competitive landscape of the Antimicrobial Resistance Surveillance Market involves assessing the competitive landscape to understand the strengths, weaknesses, opportunities, and threats of the industry. Key industry players have recognized that the adoption of Antimicrobial Resistance Surveillance technology holds the potential for further growth. The growing desire among producers to optimize their production costs has spurred collaborative efforts among companies to scale up their production capacity. This strategic collaboration not only aims to increase revenue but also seeks to establish dominance in the market.

The Antimicrobial Resistance Surveillance Market is highly competitive, with numerous companies vying for market share. Prominent companies in the Antimicrobial Resistance Surveillance Market include:

Major Players:

bioMérieux

BD (Becton, Dickinson and Company)

Thermo Fisher Scientific

Roche Diagnostics

Danaher Corporation

Recent Developments:

To lessen the burden of antimicrobial resistance, Boehringer Ingelheim, bioMérieux, and Evotec SE jointly announced in July 2022 the formation of a venture to develop actionable diagnostics and the next generation of medicines. With 80% of the entire expenditure going towards the battle against antimicrobial resistance, bioMerieux's priority within this joint venture will be on developing testing solutions for antibiotic resistance.

BioMerieux announced the acquisition deal with Specific Diagnostics in April 2022. Its reputation in the global market for antimicrobial resistance diagnostics has increased as a result of this calculated action.